gdc
Skin CancerSlideshows

July is UVC Safety Awareness Month

View this slideshow to learn how to protect yourself from harmful ultraviolet radiation.
Web Exclusives – July 17, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • end

Share this:

Recommended For You
Skin Cancer
Libtayo Extends Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
ImmunotherapySkin Cancer
Libtayo Reduces Pain, Improves Quality of Life in Patients with Advanced Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
ImmunotherapySkin Cancer
Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC.
Last modified: July 17, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country